Novo Nordisk A/S $NVO Shares Sold by Sunbelt Securities Inc.

Sunbelt Securities Inc. reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 73.1% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 5,741 shares of the company’s stock after selling 15,575 shares during the period. Sunbelt Securities Inc.’s holdings in Novo Nordisk A/S were worth $211,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. Capital Investment Counsel LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $3,727,000. Marathon Capital Management grew its holdings in shares of Novo Nordisk A/S by 43.9% in the fourth quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after purchasing an additional 25,230 shares during the period. Burney Co. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $1,374,000. Burkett Asset Management Ltd acquired a new stake in Novo Nordisk A/S during the fourth quarter worth about $1,823,000. Finally, XXEC Inc. increased its position in Novo Nordisk A/S by 487.1% during the first quarter. XXEC Inc. now owns 545,020 shares of the company’s stock worth $20,029,000 after purchasing an additional 452,185 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $47.20 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a market capitalization of $210.74 billion, a P/E ratio of 11.08, a PEG ratio of 4.30 and a beta of 0.77. The company has a 50 day moving average price of $46.92 and a 200 day moving average price of $45.50. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. Equities research analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on NVO shares. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Finally, Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Five equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.